In its first license agreement for small-molecule compounds, Emisphere Technologies Inc. signed on with F. Hoffmann-La Roche Ltd. to develop oral formulations of approved therapies for bone-related diseases. (BioWorld Today)

Demonstrating a 40 percent response rate in high-grade cervical dysplasia patients, Stressgen Biotechnologies Corp.'s lead candidate, HspE7, appears to be heading toward another Phase III trial. (BioWorld Today)

Losing half of its value, Genta Inc.'s stock slid south on Tuesday following news that Genasense did not meet key secondary endpoints and had safety issues in a Phase III trial, causing Aventis to drop out as a marketing partner. (BioWorld Today)